The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present at the XVIIIth International Symposium on Atherosclerosis in Toronto, Canada, June the 9th-12th, 2018

News detail

Return to all news & events

06/10/2018 Physiogenex to present at the XVIIIth International Symposium on Atherosclerosis in Toronto, Canada, June the 9th-12th, 2018

During the poster session, Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model.
Another study dealing with the effects of obeticholic acid on atherosclerosis and NASH in LDL-r KO mice will be presented by Dr. François Briand, Director of Research and Business Development, during the morning poster session on Tuesday, June the 12th (session# CS 3-10: Type 2 Diabetes: A Persistent Challenge).

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.